Melanoma Clinical Trials in Portland

Showing 81-100 of 161 trials

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

NCT01621490

The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced)

Advanced MelanomaMetastatic Melanoma

Bristol-Myers Squibb170 participantsStarted Sep 2012

Los Angeles, California, United States • Chicago, Illinois, United States • Lutherville, Maryland, United States +11 more locations

COMPLETEDPhase 2< 1 mile

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

NCT02159066

The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.

Melanoma

Pfizer158 participantsStarted Jul 2014

Los Angeles, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +29 more locations

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Melanoma Trials in Other Cities

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Vascular Response to Brachytherapy Using Functional OCT

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Safety Study of SEA-CD40 in Cancer Patients

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Study in Subjects With Small Primary Choroidal Melanoma

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Other Conditions in Portland